Floatz logo

Nurown Msc-Ntf Cells

Chronic Progressive Multiple Sclerosis

Brainstorm-Cell TherapeuticsCell therapyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Chronic Progressive Multiple Sclerosis cohort.

Asset / SponsorPhaseRating
D-thioctic acid
Rebecca Spain
Phase 2/3BB
Cyclophosphamide
Bruce Cree
Phase 3BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Centre Hospitalier de PAU
Phase 2B
Masitinib
AB Science
Phase 3B
N-Acetyl-L-Cysteine
University of California, San Francisco
Phase 2B

View all 29 →

Same molecule, other indications

Nurown Msc-Ntf Cells is also rated in:

amyotrophic lateral sclerosisDormant
BB
Indicative ·
66 / 100
View asset →
amyotrophic lateral sclerosisDormant
B
Indicative ·
60 / 100
View asset →
Multiple SclerosisDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →